Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications
Open Access
- 29 July 2023
- journal article
- review article
- Published by MDPI AG in Metabolites
- Vol. 13 (8) , 897
Abstract
Because of the high research and development cost of new drugs, the long development process of new drugs, and the high failure rate at later stages, combining past drugs has gradually become a more economical and attractive alternative. However, the ensuing problem of drug–drug interactions (DDIs) urgently need to be solved, and combination has attracted a lot of attention from pharmaceutical researchers. At present, DDI is often evaluated and investigated from two perspectives: pharmacodynamics and pharmacokinetics. However, in some special cases, DDI cannot be accurately evaluated from a single perspective. Therefore, this review describes and compares the current DDI evaluation methods based on two aspects: pharmacokinetic interaction and pharmacodynamic interaction. The methods summarized in this paper mainly include probe drug cocktail methods, liver microsome and hepatocyte models, static models, physiologically based pharmacokinetic models, machine learning models, in vivo comparative efficacy studies, and in vitro static and dynamic tests. This review aims to serve as a useful guide for interested researchers to promote more scientific accuracy and clinical practical use of DDI studies.Keywords
Funding Information
- National Natural Science Foundation of China (32273063)
This publication has 100 references indexed in Scilit:
- Comparison of intranasal and intramuscular ketamine-midazolam combination in catsVeterinary Anaesthesia and Analgesia, 2015
- In vitroprofiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYPXenobiotica, 2014
- The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI RiskDrug Metabolism and Disposition, 2014
- Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational DrugClinical Pharmacology & Therapeutics, 2013
- Development of a Physiologically‐Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A ContentCPT: Pharmacometrics & Systems Pharmacology, 2013
- Activity of Oxantel Pamoate Monotherapy and Combination Chemotherapy against Trichuris muris and Hookworms: Revival of an Old DrugPLOS Neglected Tropical Diseases, 2013
- Simultaneous Determination of Multiple CYP Inhibition Constants using a Cocktail-Probe Approach2013
- Evaluation of the Use of Static and Dynamic Models to Predict Drug-Drug Interaction and Its Associated Variability: Impact on Drug Discovery and Early DevelopmentDrug Metabolism and Disposition, 2012
- Development of an in vitro drug–drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compoundsJournal of Pharmacological and Toxicological Methods, 2008
- In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horsesAmerican Journal of Veterinary Research, 2008